Predict the Risk of Prostate Cancer at Re-Biopsy
Developed by Miraca Life Sciences, this new test helps treating physicians to predict the risk of prostate cancer at re-biopsy for patients with high-grade prostatic intraepithelial neoplasia (HGPIN).
Which HGPIN patients need re-biopsy?
Which HGPIN patients need conservative follow-up?
Miraca independent research suggests a high-risk (≈60%) of discovering prostate cancer upon re-biopsy when testing positive for PINgenius, combined with certain histological risk factors.
- High-grade prostatic intraepithelial neoplasia (HGPIN) is a putative precursor lesion to prostate cancer
- Men with an isolated HGPIN diagnosis from a prostate biopsy are at risk of harboring or developing prostate cancer at repeat biopsy
- Existing clinical and pathological risk-assessment tools have not accurately and consistently identified which patients should be conservatively followed and which patients will need a repeat biopsy
- The PINgenius test employs biomarker overexpression as well as several histological factors to help gauge the risk of prostate cancer at repeat biopsy.
If PINgenius result suggests HIGH RISK—Repeat biopsy may be indicated.
If PINgenius result suggests LOW RISK—Conservative follow up may be indicated; delay or avoid re-biopsy unless other clinical parameters require rebiopsy.
*NOTE: The timeframe to schedule re-biopsy is a decision made between the physician and patient.
Park K et al. TMPRSS2: ERG Gene Fusion Predicts Subsequent Detection of Prostate Cancer in Patients with High-grade Prostatic Intraepithelial Neoplasia. Journal of Clin Oncology, 2013
Shah RB. Clinical Application of Novel ERG immunohistochemistry in Prostate Cancer Diagnosis and Management. Review. Adv Anat Pathol, 20(2): 117–24, 2013
Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010;13:228–37.
Learn more about the PINgenius test!